Treatment of Hemophilia in Children

In contemporary times, the domain of hemophilia therapeutics has experienced a notable evolution, with an extensive array of long half-life coagulation factors being introduced to the market. Additionally, the incorporation of non-coagulation factor products into treatment regimes has significantly broadened the spectrum of available options for individuals diagnosed with this condition. Notably, the recent authorization of gene therapy products introduces a revolutionary shift, presenting the potential to transform the conventional modalities of hemophilia management. The focal point of this Research Topic will be an exploration of hemophilia treatment among pediatric populations, with the aim of serving as a useful resource for medical practitioners in their clinical decision-making processes.

The goal of this Research Topic is to promote the prophylaxis of hemophilia in children and explore treatment of hemophilia inhibitors in children. In addition, we would like to learn about hemophilia gene therapy.

We cordially invite authors to present their premium and original basic, applied, or clinical research pertaining to this subject matter. Submissions of authoritative review papers are more than welcome. We also put into consideration unique case reports or series, featuring innovative techniques, advancements in treatment, or any pertinent clinical findings.

The following topics would be of special interest:

● Prophylaxis of hemophilia in children

● The management of inhibitor in hemophilia children

● Advances in the application of the gene therapy in hemophilia

Keywords: Haemophilia, children, prophylaxis, inhibitor management, gene therapy

Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.